Antibody-mediated cell entry of SARS-CoV-2
暂无分享,去创建一个
D. Wesemann | Haisun Zhu | Hang Xie | Hanqin Peng | Bing Chen | Shaowei Wang | M. Seaman | W. Shi | M. G. Kibria | C. Lavine | Caihong Bi | Sophia Rits-Volloch | Jianming Lu | Weichun Tang | H. Gao | Jewel Voyer | Keerti | Hailong Gao
[1] J. Theiler,et al. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1 , 2023, The New England journal of medicine.
[2] A. Gordon,et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants , 2022, Cell.
[3] Haisun Zhu,et al. Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane , 2022, bioRxiv.
[4] S. Pittaluga,et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy , 2022, Nature.
[5] Theresa L. Chang,et al. ACE2-Independent Alternative Receptors for SARS-CoV-2 , 2022, Viruses.
[6] Benjamin Bowe,et al. Acute and postacute sequelae associated with SARS-CoV-2 reinfection , 2022, Nature Medicine.
[7] J. Yewdell,et al. Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond , 2022, iScience.
[8] F. Alt,et al. An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion , 2022, Science Immunology.
[9] S. Whelan,et al. SARS-CoV-2 requires acidic pH to infect cells , 2022, bioRxiv.
[10] D. Neuberg,et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants , 2022, Science immunology.
[11] J. Lieberman,et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation , 2022, Nature.
[12] A. Telenti,et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.
[13] Rong-Fong Shen,et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains , 2021, Nature Communications.
[14] M. Farzan,et al. Mechanisms of SARS-CoV-2 entry into cells , 2021, Nature reviews. Molecular cell biology.
[15] S. Subramaniam,et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding , 2021, bioRxiv.
[16] J. Mascola,et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.
[17] M. Beltramello,et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.
[18] S. Boulant,et al. TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells , 2021, The EMBO journal.
[19] C. Woods,et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies , 2021, Cell.
[20] M. Giacca,et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.
[21] P. Taylor,et al. Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.
[22] D. Neuberg,et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike , 2021, bioRxiv.
[23] Bingjun Wang,et al. ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species , 2021, Nature Ecology & Evolution.
[24] Helio T. Navarro,et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia , 2020, Nature.
[25] Weijin Huang,et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development , 2020, Signal Transduction and Targeted Therapy.
[26] A. Griffiths,et al. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent , 2020, Nature Structural & Molecular Biology.
[27] Yongfei Cai,et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution , 2020, bioRxiv.
[28] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[29] T. Ideker,et al. Functional Landscape of SARS-CoV-2 Cellular Restriction , 2020, bioRxiv.
[30] Peter B Rosenthal,et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion , 2020, Nature.
[31] S. Kent,et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.
[32] Ralf Bartenschlager,et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.
[33] J. Ravetch,et al. The role of IgG Fc receptors in antibody-dependent enhancement , 2020, Nature Reviews Immunology.
[34] Catherine Z. Chen,et al. Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles , 2020, bioRxiv.
[35] Beata Turoňová,et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges , 2020, Science.
[36] I. Trougakos,et al. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators , 2020, Redox Biology.
[37] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[38] J. Sodroski,et al. Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike , 2020, bioRxiv.
[39] D. Lauffenburger,et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.
[40] Shaun Rawson,et al. Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.
[41] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[42] Fabian J Theis,et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.
[43] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[44] K. Shi,et al. Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.
[45] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[46] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[47] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[48] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[49] D. Veesler,et al. Structural insights into coronavirus entry , 2019, Advances in Virus Research.
[50] D. Cummings,et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk , 2018, Nature.
[51] M. Halloran,et al. Antibody-dependent enhancement of severe dengue disease in humans , 2017, Science.
[52] J. Taubenberger,et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.
[53] G. Whittaker,et al. Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection. , 2016, Bio-protocol.
[54] Hanqin Peng,et al. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein , 2015, Science.
[55] K. Tsumoto,et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI , 2015, Nature Communications.
[56] M. Kielian. Mechanisms of Virus Membrane Fusion Proteins. , 2014, Annual review of virology.
[57] R. Baric,et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus , 2014, Proceedings of the National Academy of Sciences.
[58] Yi Shi,et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.
[59] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[60] Sjors H.W. Scheres,et al. RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.
[61] Yi-Lun Lin,et al. Structural basis for multifunctional roles of mammalian aminopeptidase N , 2012, Proceedings of the National Academy of Sciences.
[62] Fang Li,et al. Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor , 2011, Proceedings of the National Academy of Sciences.
[63] S. Harrison. Viral membrane fusion , 2008, Nature Structural &Molecular Biology.
[64] J. Ravetch,et al. Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.
[65] Ben Berkhout,et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[66] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[67] B. Bosch,et al. The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.
[68] S. Harrison,et al. Structural basis for membrane fusion by enveloped viruses. , 1999, Molecular membrane biology.
[69] T. Saito,et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. , 1996, Blood.
[70] A. Look,et al. Human aminopeptidase N is a receptor for human coronavirus 229E , 1992, Nature.
[71] B. Delmas,et al. Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV , 1992, Nature.
[72] C. Dieffenbach,et al. Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV , 1991, Journal of virology.
[73] SB Halstead,et al. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.